Background and purpose: Cytomegalovirus (CMV) infection has recently been associated with a lower multiple sclerosis (MS) susceptibility, although it remains controversial whether it has a protective role or is merely an epiphenomenon related to westernization and early-life viral infections. We aimed to evaluate whether CMV serostatus may differ in patients with early MS as compared with patients with non-early MS, analyzing the putative association of this virus with MS clinical course and humoral immune responses against other herpesviruses. Methods: Multicentric analysis was undertaken of 310 patients with MS (early MS, disease duration ≤5 years, n = 127) and controls (n = 155), evaluating specific humoral responses to CMV, Epstein-Barr virus and human herpesvirus-6, as well as T-cell and natural killer (NK)-cell immunophenotypes. Results: Cytomegalovirus seroprevalence in early MS was lower than in nonearly MS or controls (P < 0.01), being independently associated with disease duration (odds ratio, 1.04; 95% confidence interval, 1.01-1.08, P < 0.05). CMV+ patients with MS displayed increased proportions of differentiated T-cells (CD27ÀCD28À, CD57+, LILRB1+) and NKG2C+ NK-cells, which were associated with a lower disability in early MS (P < 0.05). CMV+ patients with early MS had an age-related decline in serum anti-EBNA-1 antibodies (P < 0.01), but no CMV-related differences in anti-human herpesvirus-6 humoral responses. Conclusions: Low CMV seroprevalence was observed in patients with early MS. Modification of MS risk attributed to CMV might be related to the induction of differentiated T-cell and NK-cell subsets and/or modulation of Epstein-Barr virus-specific immune responses at early stages of the disease.
Introduction
Multiple sclerosis (MS) is believed to be caused by a complex interplay between genetic and environmental risk factors (e.g. herpesvirus infections). Most evidence supports a role of Epstein-Barr virus (EBV), a gammaherpesvirus almost universally present in patients with MS [1] . Other herpesviruses [e.g. human herpesvirus-6 (HHV-6)] have also been related to MS [2] . By contrast, recent studies have associated cytomegalovirus (CMV) infection with a decrease in MS susceptibility [3] [4] [5] , although a causal relation and the mechanisms underlying a putative protective effect remain controversial [6] . However, the influence of herpesviruses in MS seems to be more marked at early stages of the disease, as evaluated by specific immune responses [7] [8] [9] .
Cytomegalovirus is a beta-herpesvirus that establishes a lifelong infection in 60-100% of human populations. Substantial immunological resources are devoted to control of CMV infection, leading to an 'inflation' of terminally differentiated T-cells that has been related to immunosenescence [10] . In addition, CMV may induce an adaptive differentiation and persistent expansion of an NKG2C+ natural killer (NK)-cell subset [11] , and this effect has been recently associated with decreased MS progression [12] . Herpesvirus coinfections might have additional immunological implications that influence the responses against other pathogens [13] [14] [15] . In this study, we evaluated whether CMV infection and its imprint on the T-cell and NK-cell compartments may differ in early MS as compared with patients with non-early MS, analyzing the putative association of this virus with MS clinical course and humoral immune responses against EBV and HHV-6.
Methods

Patients with multiple sclerosis and controls
A cross-sectional multicenter study was performed in three hospitals integrated in the Spanish Network for MS Research (Red Española de Esclerosis M ultiple) where patients with MS were prospectively recruited from routine clinical visits. Patients (n = 310) met MS criteria based on McDonald 2010. Exclusion criteria were: (i) a relapse within 30 days prior to inclusion, (ii) any severe concomitant disease, (iii) pregnancy and (iv) disease-modifying drug (DMD) therapy known to deplete peripheral lymphocytes or alter their trafficking (i.e. fingolimod, natalizumab). Healthy controls (n = 155) were included from the same geographic area as patients. Clinical variables (Table 1) were evaluated at the time of the analysis, including DMD treatment (interferon-beta, n = 80; glatiramer acetate, n = 8). Early MS (n = 127; median time from onset, 1.33 years) was defined as a disease duration of ≤5 years from the first clinical demyelinating event, with the remaining patients classified as having nonearly MS (n = 183; median time from onset, 16 years). Blood samples from venous puncture were obtained for serological and immunological analysis. The study was approved by the Hospital del Mar Medical Research Institute Ethics Committee and patients gave written informed consent.
Immunological analysis of peripheral blood lymphocyte subsets
Peripheral blood mononuclear cells were isolated from blood samples taken in EDTA collection tubes using Lymphoprep, and subsequently cryopreserved in fetal calf serum with 10% dimethyl sulfoxide. The gating strategy of the study is shown in Fig. 1 . NK-cell immunophenotype was evaluated in patients with early MS (n = 120) as previously reported [12] , using the following conjugated monoclonal antibodies: anti-CD3-PerCP, anti-CD56-APC (BD Biosciences), NKG2C-PE (R&D Systems) and 4 0 ,6-diamidino-2-phenylindole (DAPI). A selected panel of immunological markers of differentiated/senescent T-cells previously related to CMV infection (CD27ÀCD28À/CD57+/LILRB1+ Tcells) [16] [17] [18] was evaluated in a subcohort of patients with MS (early MS, n = 35; non-early MS, n = 32) and controls (n = 32) stratified for CMV serology. Samples were stained by indirect immunofluorescence with LILRB1 HP-F1 and anti-mouse Ig-PE-Cy7 (Biolegend), washed and further incubated with anti-CD3-APC-H7, anti-CD27-PERCP-Cy5.5, anti-CD28-PE-CF594, CD57-PE (BD Biosciences), anti-CD4-FITC (eBioscience) and anti-CD8-BV510 (Biolegend). All samples were analyzed at the Flow Cytometry Unit (University Pompeu Fabra/Centre for Genomic Regulation, Barcelona, Spain) with an LSRII-Fortessa flow cytometer (BD Biosciences).
Analysis of humoral responses to herpesviruses
Standard clinical diagnostic tests to evaluate CMV-and EBV-specific circulating antibodies were performed in serum samples (BioM erieux). Enzyme-linked immunosorbent assays were performed in subcohorts of patients with MS (early MS, n = 59; non-early MS, n = 50) and controls (n = 101) for quantitative determination of anti-EBNA-1 IgG and anti-VCA IgG (Trinity Biotech), anti-CMV IgG and IgM (Vircell), and anti-HHV-6 A/B IgG and IgM (Vidia) with commercially available kits following the manufacturer's instructions. Results were expressed as an index value that was calculated as follows: [10 9 (sample absorbance/cut-off value)]. Samples were analyzed in duplicate and doubtful samples (index value 9-11) were reanalyzed.
Statistical analysis
After assessment of normal distribution using normal Q-Q probability plots, continuous variables were expressed as mean AE SD or median (first-third quartile) for parametric and non-parametric variables, respectively. The relationship between continuous and (Fig. 2a) . However, CMV seroprevalence in patients with early MS (48%) was significantly lower compared two by two with patients with non-early MS (65%, P < 0.01) and controls (63.8%, P < 0.01) (Fig. 2b) . Subsequently, cases were age categorized as ≤40 or >40 years old. CMV seroprevalence was significantly lower in cases ≤40 years of age as compared with cases >40 years of age in both patients with MS (P < 0.001) and controls (P < 0.05) (Fig. 2c) . Patients with MS of ≤40 years of age had a significant lower CMV seroprevalence as compared with controls of ≤40 years of age (45% vs. 67%, P < 0.05), but there were no differences between patients and controls of >40 years of age (Fig. 2c) .
No other clinical differences were associated with CMV seroprevalence in early MS (Table 1) . A logistic regression analysis of the whole MS cohort showed that CMV seroprevalence was significantly associated with disease duration (odds ratio, 1.04; 95% confidence interval, 1.01-1.08, P < 0.05), independent of age (odds ratio, 1.02; 95% confidence interval, 0.99-1.04, P = 0.190).
Cytomegalovirus-driven NKG2C+ natural killer cell expansion in patients with early multiple sclerosis
We subsequently evaluated the CMV imprint on the NK-cell compartment of patients with early MS (n = 120). As previously reported [12] , CMV seropositivity was associated with higher %NKG2C+ NKcells in patients with early MS (CMVÀ: 10.9 AE 5.7% vs. CMV+: 18.8 AE 16.5%, P < 0.01) and controls (CMVÀ: 11.6 AE 8.2% vs. CMV+: 21.5 AE 19.2%, P < 0.05).
Classifying cases according to the magnitude of the NKG2C expansion, patients with early MS with high %NKG2C+ NK-cells had lower disability scores as compared with patients with low %NKG2C+ NKcells (Table 1) . No significant differences were found Figure 2 Cytomegalovirus (CMV) serostatus in patients with multiple sclerosis (MS) (□) and controls (■). (a) CMV seroprevalence in patients with MS and controls, (b) according to MS duration (early MS, ≤5 years) and (c) categorizing cases according to age of ≤40 and >40 years. *P < 0.05; **P < 0.01; ***P < 0.001. when analyzing proportions of NKG2C+ T-cells (early MS, 2.2 AE 2.0%; non-early MS, 1.7 AE 2.0%; controls, 1.8 AE 1.9%, P = 0.187). No additional differences were observed for cerebrospinal fluid oligoclonal bands evaluated in a subcohort of 74 patients with early MS (Table S1 ).
Association of cytomegalovirus seropositivity with increased proportions of terminally differentiated T-cells in patients with multiple sclerosis
In order to evaluate the influence of CMV on the Tcell compartment, the expression of immunological markers of terminal differentiation was analyzed in a subcohort of patients with MS (early MS, n = 35; non-early MS, n = 32) and controls (n = 32). CMV seropositivity in patients and controls was associated with significantly higher proportions of CD27ÀCD28À, CD57+ and LILRB1+ in CD8+ Tcells (Fig. 3a) , independent of age and MS duration. With regard to CD4+ T-cells, CMV induced a less pronounced terminal differentiation than in CD8+ T-cells, and was mainly observed in early MS and controls as compared with non-early MS (Fig. 3b) . Controls and patients with non-early MS showed an age-related increase in differentiated CD8+ T-cells, without additional differences observed according to DMD therapy (Table S2) or other clinical characteristics (data not shown).
Humoral immune responses to herpesviruses in early multiple sclerosis
Virus-specific antibodies against CMV, EBV and HHV-6 were evaluated in early MS (n = 59, 8 DMDtreated cases), non-early MS (n = 50, 18 DMD-treated cases) and controls (n = 101). Seroprevalences for herpesviruses in early MS compared with controls were as follows: CMV+, 44.1% vs. 63% (P < 0.05), EBV+, 98.3% vs. 88.5% (P < 0.05) and HHV-6+, 87.9% vs. 89% (P = 0.515). When evaluating virus-specific quantitative indices in seropositive individuals, patients with MS had a significantly higher EpsteinBarr nuclear antigen (EBNA)-1 index as compared with controls (24.25 AE 4.96 vs. 18.93 AE 4.06, P < 0.0001) independent of MS duration (Fig. 4a) . Anti-VCA index was similar in patients with early MS and controls (data not shown). No differences were observed for CMV or HHV-6 indices according to MS duration (Fig. 4b and c) .
The putative influence of CMV infection with humoral responses to other herpesviruses was subsequently studied in individuals coinfected with EBV and HHV-6 (early MS, n = 30; non-early MS, n = 23; Figure 3 Terminally differentiated T-cells in patients with multiple sclerosis (MS) and controls according to cytomegalovirus (CMV) serostatus and MS duration. Percentages of CD27ÀCD28À, CD57+ and LILRB1+ were evaluated in CD8+ T-cells (a) and CD4+ Tcells (b). *P < 0.05; **P < 0.01; ***P < 0.001. ■, CMV(+); □, CMV(À). controls, n = 52). CMV serostatus had no relationship with EBNA-1 or HHV-6 indices in patients with MS and controls ( Fig. 4d and e) . However, an inverse correlation between anti-EBNA-1 and MS duration was observed in CMV+ patients with MS (R Spearman À0.59, P < 0.01) but not in CMV seronegative cases (Fig. 5) , suggesting a progressive reduction in EBV humoral responses after MS onset in CMV-infected patients. No additional differences were detected regarding proportions of NKG2C+ NK-cells or DMD therapy (data not shown).
The CMV IgG index was directly correlated with some markers of terminal differentiation in CD4+ and CD8+ T-cells in CMV+ patients with MS and controls (Table S3) . EBV humoral responses were not related to NKG2C+ NK-cell expansion or terminally differentiated T-cells, except for an inverse correlation of EBNA-1 index in early MS with percentages of CD3+CD56+ T-cells (R Spearman À0.55, P < 0.01), independent of CMV and HHV-6 serostatus. No correlations between EBV and HHV-6 serostatus and T-cell differentiation markers were found in patients with MS or controls (data not shown).
Discussion
Infections have been considered as potential environmental factors involved in MS pathogenesis. EBV is the main pathogen suspected to be related to MS, suggesting the implication of virus-triggered immunological responses [1, 9] . In contrast, some recent evidence supports an inverse association between CMV and MS risk in pediatric and adult populations [3] [4] [5] . Our study shows a low CMV seroprevalence rate in early MS independent of age at disease onset, pointing to epidemiological differences related to previous herpesvirus primary infections at early stages of the disease, in line with a putative protective role of CMV in MS.
Globally, CMV seroprevalence varies from an almost universal infection in undeveloped countries to 60-80% in western populations. CMV is transmitted through secretions and primary infection often occurs in early childhood. In this regard, we did not find serological evidence of CMV primary infection in early MS, except for three cases. Differences in seroprevalence for herpesviruses found in early MS might be related to the 'hygiene hypothesis', which proposes that early exposure in life to certain pathogens may be protective against autoimmune diseases, as opposed to a higher risk conferred by late primary infections [1] . The low CMV seroprevalence observed in early MS might be interpreted according to the 'old friends' reformulation of the 'hygiene hypothesis', which attributes the increase in autoimmune disorders related to western lifestyle to a loss of symbiotic relationships with micro-organisms that have a long-lasting coevolution with humans [19] .
Persistent CMV infection may have functional implications in the immune system, with a potential impact on the development of autoimmune diseases [20] . CMV develops a variety of immunoevasion strategies leading to complex host-virus interactions. Expansions of oligoclonal CMV-specific effectormemory T-cell populations are detected in CMV+ individuals and tend to increase with age [10] . Such 'memory inflation' reflects an accumulation of oligoclonal differentiated T-cells, which have a limited proliferative capacity but maintain their effector functions upon antigen stimulation [16, 18] . The reduced diversity of the CD8+ T-cell compartment has been related to immunosenescence and potentially limits the development of immune responses to unrelated antigens [10, 18, 21] . Based on our results, increased proportions of terminally differentiated T-cells were observed in CMV+ patients with MS. Presumably, CMV seronegative patients with MS close to disease onset develop the inflammatory process involving a pool of lessdifferentiated T-cells as compared with CMV+ individuals. In this setting, persistent CMV infection might divert immunological resources, reducing the risk of autoimmunity, in line with the hypothesis that it may be protective for MS development [4, 5] .
However, CMV infection may also have a positive indirect effect in the control of other viral infections. Previous exposure to some pathogens may modify specific immune responses to unrelated pathogens, a phenomenon termed 'heterologous immunity', which can be mediated by innate responses as well as crossreactive T-cells, bystander activation of T-cells and humoral responses [14, 15] . Chronic infections may modify specific immunity against other pathogens, impairing the development of CD8+ T-cell memory responses and inducing contraction of specific T-cell populations [22, 23] . In particular, CMV may increase the production of proinflammatory cytokines (e.g. tumor necrosis factor-a and interferon-c) and antibody-dependent cell cytotoxicity mediated by adaptive NK-cells, which may influence immune responses to other pathogens [13, 24] . On this basis, we analyzed specific humoral responses in patients with MS according to CMV serostatus, observing a decrease in EBNA-1 index related to disease duration in CMV+ patients with early MS. In contrast, no CMV-related differences were found when HHV-6 humoral responses were analyzed. As anti-EBNA-1 antibody levels were previously shown to directly correlate with higher MS disease activity [1, 8] and EBV-specific CD8+ T-cells [7] , further studies are needed to evaluate whether this CMV-related reduction in anti-EBNA-1 levels could be associated with decreased virus-specific T-cell responses.
In contrast to several pieces of evidence supporting a protective role of CMV in MS [3] [4] [5] 12] , other reports suggest a higher MS risk induced by this virus [6, 25] , an effect that could be related to the detrimental effect of CMV primary infection by increasing the inflammatory process in MS [6, 25] . Nevertheless, our observations are consistent with a putative influence of a non-primary CMV infection in early MS. We did not find any significant clinical differences in early MS according to CMV serostatus. However, based on our results, lower disability scores at early stages of MS were associated with NKG2C+ NK-cell expansion, in accordance with a previous study describing a lower risk of long-term progression in patients with MS displaying such an NK-cell adaptive CMV imprint [12] .
In conclusion, patients with early MS in our study were characterized by low CMV seroprevalence, suggesting that disease duration may be a relevant variable in studies analyzing the influence of this virus on MS risk. It is tempting to speculate that missing a potential 'old friend' such as CMV could be associated with increased susceptibility for autoimmunity. By contrast, exposure to CMV in early childhood and the imprint of the virus on the immune system might influence the development of immune responses to other herpesviruses infections and decrease the risk of MS. The putative protective role conferred by CMV in early stages of MS remains to be addressed in further studies.
